Global drug discovery market will reach $117.6 billion by 2030, growing by 8.6% annually over 2020-2030 driven by the rising demand for specialty medicines, the surge in lifestyle-oriented diseases and the advancements in technology, the growing elderly population and the rising healthcare expenses, rising expenditure on R&D, and expiration of patents.
Highlighted with 86 tables and 97 figures, this 181-page report Global Drug Discovery Market 2020-2030 by Drug Type (Small Molecule, Biologics), Service (Medicinal, Biological, DMPK), Process, Technology, Therapeutic Area, End User, and Region: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire global drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
Market Structure
Growth Drivers
Restraints and Challenges
Emerging Product Trends & Market Opportunities
Porters Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global drug discovery market in every aspect of the classification from perspectives of Drug Type, Service, Process, Technology, Therapeutic Area, End User, and Region.

Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
Small Molecule Drugs
Biologic Drugs

Based on Service, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
Medicinal Chemical Services
Biological Services
Drug Metabolism and Pharmacokinetics (DMPK) Services
Other Pharmaceutical Services

Based on Process, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
Target Selection
Target Validation
Hit-To-Lead Identification
Lead Optimization
Candidate Validation

Based on Technology, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
High Throughput Screening
Combinatorial Chemistry
Pharmacogenomics and Pharmacogenetics
Nanotechnology
Bioanalytical Instruments
Biochips
Bioinformatics
Other Technologies

Based on Therapeutic Area, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
Oncology
Neurology
Infectious and Immune System Diseases
Digestive System Diseases
Cardiovascular Diseases
Diabetes
Respiratory Disease
Other Therapeutic Areas

Based on End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
Pharmaceutical Companies
Contract Research Organizations (CROs)
Research Institutes
Other End Users

Geographically, the following regions together with the listed national/local markets are fully investigated:
North America (U.S., Canada, and Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
South America (Brazil, Chile, Argentina, Rest of South America)
MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Drug Type, Service, and Therapeutic Area over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories Inc.
Agilent Technologies Inc.
Astrazeneca plc
Bayer AG
Charles River Laboratories International Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Shimadzu Corp
Thermo Fisher Scientific Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)